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BACKGROUND: The aggressive B-cell non-Hodgkin lymphomas diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma
(MCL) are characterised by a high proliferation rate. The anaphase-promoting complex/cyclosome (APC/C) and its co-activators
Cdc20 and Cdh1 represent an important checkpoint in mitosis. Here, the role of the APC/C and its co-activators is examined in
DLBCL and MCL.
METHODS: The expression and prognostic value of Cdc20 and Cdh1 was investigated using GEP data and immunohistochemistry.
Moreover, the therapeutic potential of APC/C targeting was evaluated using the small-molecule inhibitor proTAME and the
underlying mechanisms of action were investigated by western blot.
RESULTS: We demonstrated that Cdc20 is highly expressed in DLBCL and aggressive MCL, correlating with a poor prognosis in
DLBCL. ProTAME induced a prolonged metaphase, resulting in accumulation of the APC/C-Cdc20 substrate cyclin B1, inactivation/
degradation of Bcl-2 and Bcl-xL and caspase-dependent apoptosis. In addition, proTAME strongly enhanced the anti-lymphoma
effect of the clinically relevant agents doxorubicin and venetoclax.
CONCLUSION:We identified for the first time APC/C as a new, promising target in DLBCL and MCL. Moreover, we provide evidence
that Cdc20 might be a novel, independent prognostic factor in DLBCL and MCL.
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BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) and mantle cell
lymphoma (MCL) are among the most common aggressive
B-cell non-Hodgkin lymphomas (NHL). Although the standard-
of-care regimen R-CHOP (rituximab, cyclophosphamide, doxor-
ubicin, vincristine and prednisone) has significantly improved
the survival rates, MCL remains incurable and up to one-third of
the DLBCL patients are or become refractory.1,2 Within the
DLBCL patients, two major DLBCL subtypes are identified by
gene expression profiling: germinal centre B cell (GCB) and
activated B-cell (ABC) DLBCL, of which the ABC–DLBCL subtype
has a worse clinical outcome.3
The clinical use of cell cycle targeting agents, such as the
microtubule-targeting agent vincristine, has proven that this is an
interesting approach in the treatment of high-grade B-cell NHL.4
However, these agents induce severe toxicity and are associated
with multidrug resistance development.5 Clinical studies are
currently ongoing to find more selective cell cycle targets by
blocking either the interphase (e.g. Cdk inhibitors) or mitotic entry
(e.g. microtubule-targeting agents, Plk-1 and aurora kinase
inhibitors).6 In B-cell NHL, the anti-lymphoma effects of these
agents were either disappointing or the trials were suspended
early due to toxicity issues.6–9 Recent preclinical studies show that
targeting molecules involved in the mitotic exit, such as the
anaphase-promoting complex/cyclosome (APC/C), is a better
strategy since it provokes a more permanent mitotic arrest,
thereby reducing the chance of mitotic slippage and thus
enhancing mitotic cell death.10 The activation of the APC/C, an
E3-ubiquitin ligase, depends on the interaction with its co-
activators Cdc20 or Cdh1. The spindle assembly checkpoint
(SAC) prevents APC/C activation in early mitosis. When bi-
orientation of the chromosomes is achieved in the metaphase,
the SAC pathway is inactivated and APC/C–Cdc20 binding occurs.
This interaction leads to proteasomal degradation of the
substrates cyclin B1 and securin, subsequently allowing the onset
of the anaphase.11 Cdc20 is thereafter replaced by Cdh1 and the
APC/C–Cdh1 targets Cdc20, aurora kinases and Plk-1 during
mitotic exit. In early G1 phase, Skp2 and mitotic cyclins are
degraded, resulting in increased p21, p27 and cyclin D levels,
which is necessary to maintain the G1 phase.11,12
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Several studies have already suggested the involvement of the
APC/C and its co-activators in tumorigenesis of different cancers
and their potential as a new therapeutic target.11,13 Wang et al.
were the first to demonstrate APC/C mutations in human cancer
cells, showing that a disruption of some of the APC/C subunits
contributes to tumorigenesis by deregulation of key cell cycle
regulators.14 Increased Cdc20 expression is correlated with poor
prognosis in several human cancers,15–21 and depletion of Cdc20
in various cancer cell lines resulted in tumour metaphase arrest
and induction of apoptosis.19,22,23 Moreover, inhibition of Cdh1
has been associated with tumorigenesis and decreased Cdh1
expression is observed in breast and colon cancer.24,25 The small
molecule TAME (tosyl-L-arginine methyl ester) was discovered as a
specific APC/C inhibitor in the past decade. It mimics the IR-tail of
the co-activators and blocks the interaction between APC/C and
Cdc20 or Cdh1.26 Previously, we and others demonstrated that
proTAME (permeable variant of TAME) treatment results in a
reduced viability, a growth arrest and apoptosis of malignant
plasma cells.15,27
Currently, however, little is known about the therapeutic
potential of targeting the APC/C and its co-activators in DLBCL
and MCL. The aim of this study is to investigate the expression of
the APC/C co-activators Cdc20 and Cdh1 and the therapeutic
potential of APC/C targeting in DLBCL and MCL.
METHODS
Analysis of Cdc20 and Cdh1 gene expression levels
The publicly available GEP datasets GSE1084628,29 (containing
gene expression data and survival data of 167 ABC–DLBCL
patients, 183 GCB–DLBCL patients and 64 unclassified DLBCL
patients), GSE5631530 (containing gene expression data of 33 B-
cell samples, 23 ABC–DLBCL patients, 29 GCB–DLBCL patients
and 3 unclassified DLBDL patients), GSE1645531 (containing
gene expression data of 7 indolent and 15 aggressive MCL
patients) and GSE3613332 (containing gene expression data of
13 human DLBCL cell lines and 5 MCL cell lines) were used. Raw
CEL files were obtained from the Gene Expression Omnibus
(GEO) and gcrma-normalisation was performed in R using
bioconductor. Survival analysis of GEP microarray data was
done using Genomicscape (http://genomicscape.com). The
following probe sets were used: 202870-s-at (Cdc20) and
209416-s-at (Cdh1).
Patient biopsies and staining
Patient samples were collected at the Department of Pathology in
Brussels (UZ Brussels, Belgium) and the Department of Biopathol-
ogy in Montpellier (CHU Montpellier, France). Paraffin-embedded
samples available from seven DLBCL patients were selected in
Brussels and 3-μm-thick sections from tissue microarrays contain-
ing three representative 0.6-mm cores of routinely processed
tissues from 27 DLBCL patients were included from Montpellier.33
All samples were stained with Cdc20 antibody (ATLAS Antibodies
AB, Bromma, Sweden) using an automated immunostainer
Benchmark XT (Roche Ventana, Basel, Switzerland). As a positive
control, tonsils with secondary follicles were used. Two hundred
tumour cells were counted and the percentage of tumour cells
with a staining of any intensity was determined at a magnification
×400 on a Leica DM2000 microscope. The counting was
performed in hot-spot areas by means of an ocular grid. Based
on the R-IPI of the DLBCL patients, they were divided into good
and poor prognosis groups. Cells were scored MYC and Bcl-2
positive as we described previously.33
Cell culture
All the MCL (Jeko-1, Mino and Rec-1) and ABC–DLBCL cell lines
(U2932 and RI-1) were maintained in the RPMI-1640 medium
(Lonza, Basel, Switzerland) supplemented with 10% foetal calf
serum (FCS) (Biochrom AG, Berlin, Germany) and 2mM glutamine
(Life Technologies, Gent, Belgium). The GCB–DLBCL cell lines (SU-
DHL-6, OCI-Ly1 and OCI-Ly7) were maintained in the IMDM
medium (Life Technologies) supplemented with 10% FCS and 2
mM glutamine. Cells were cultured at 37 °C in a humidified 5%
CO2atmosphere. All cell lines were obtained from ATCC and
regularly tested for mycoplasma contamination. They were
authenticated by STR profiling.
Reagents
The APC/C inhibitor proTAME was obtained from R&D Systems
(Oxon, UK). Venetoclax and rituximab were obtained from
Selleckchem (Bio-Connect, Huissen, The Netherlands), doxorubicin
hydrochlorate was purchased from Sigma-Aldrich (Bornem,
Belgium) and apcin was kindly provided by Dr. R.W. King
(Department of Cell Biology, Harvard Medical School).
Statistical analysis
Prognostic significance of Cdc20 and Cdh1 gene expression was
calculated using the MaxStat R package. Statistical differences in
overall survival were calculated by a log-rank test and survival
curves were plotted using Kaplan–Meier method. Multivariate
analysis was performed using the Cox proportional hazards model.
Graphical and statistical analysis was performed using GraphPad
Prism 5.01 software. Statistical significance (p-value of p < 0.05 was
considered significant) was determined by a Mann–Whitney U test
(to compare two groups) and a one-way ANOVA with Bonferonni
correction for multiple testing.
More details on the ‘Methods' section are described in Supple-
mental Methods.
RESULTS
Cdc20 expression is increased in DLBCL and MCL patients and
associated with poor survival
To investigate the clinical relevance of the APC/C in the aggressive
B-cell malignancies DLBCL and MCL, the gene expression levels of
the two APC/C co-activators, namely Cdc20 and Cdh1, were
analysed using publicly available gene expression profiling (GEP)
datasets. The expression of Cdc20 and Cdh1 mRNA was assessed
in DLBCL patients, using GEP data from B-cell samples (n= 33),
ABC–DLBCL (n= 190), GCB–DLBCL (n= 212) and unclassified
DLBCL patients (n= 67). The gene expression levels of Cdc20
were significantly increased in all DLBCL subtypes compared with
the B-cell samples. In contrast, the Cdh1 gene expression levels
were not significantly different in the GCB–DLBCL and ABC–DLBCL
patients compared with the B-cell samples (Fig. 1a, b). Analysis of
gene expression levels in a MCL cohort revealed elevated Cdc20
expression levels in aggressive MCL compared with indolent MCL.
No significant difference was observed for Cdh1 expression
(Fig. 1c, d). Importantly, high Cdc20 expression levels were
associated with a worse survival in DLBCL patients receiving the
standard R-CHOP treatment. The same trend was observed for
Cdh1 and clinical outcome; however, significance was not reached
(Fig. 1e, f).
Next, the prognostic value of Cdc20 expression in DLBCL
patients was compared with conventional prognostic factors,
including the age at diagnosis, International Prognostic Index (IPI)
and molecular DLBCL subtypes. Univariate COX analysis demon-
strated that all these factors have a prognostic value in DLBCL
(Table 1A). In the multivariate COX analysis, when all parameters
were tested together, Cdc20 expression, IPI and molecular subtype
remained independent prognostic factors (Table 1B). Finally, the
protein Cdc20 expression was determined on DLBCL patient
biopsies (Fig. 1g). The percentage Cdc20-positive lymphoma cells
was counted and plotted against the patient’s prognosis
according to their R-IPI. A significant higher amount of Cdc20-
positive lymphoma cells was counted in the patients with a poor
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prognosis compared with the patients with a good prognosis (p=
0.0042) (Fig. 1h). Consistent with the multivariate COX analysis,
neither significant correlation between Cdc20 expression and
molecular subtype was found (Fig. 1i; Table 1B) nor double-
expresser status (Fig. 1j). Together, these data suggest that
increased Cdc20 expression is associated with high-grade
lymphoma and Cdc20 thus represents an interesting therapeutic
target.
Pharmacological inhibition of the APC/C decreases lymphoma cell
viability and induces apoptosis
Next, the APC/C was investigated as a potential target in DLBCL and
MCL using human cell lines. Therefore, the Cdc20 and Cdh1
expression was first determined using gene expression profiling data
of a large panel of DLBCL and MCL cell lines. Similar to the primary
patient samples, we found a significantly higher Cdc20 mRNA
expression in both the DLBCL and MCL cell lines compared with B-cell
a b
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n = 209 (89.7%)
n = 24 (10.3%)
P = 0.083, HR = 1.9
n = 209 (89.7%)


































































































B cell GCB ABC Unclassified B cell GCB ABC Unclassified Indolent Aggressive Indolent Aggressive
Fig. 1 Cdc20 mRNA expression is increased in DLBCL and MCL patients and is associated with worse survival in DLBCL patients. a, b Cdc20
and Cdh1 mRNA expression in DLBCL. Cdc20 (a) and Cdh1 (b) gene expression levels of B-cell samples (n= 33), patients with ABC–DLBCL (n=
190), patients with GCB–DLBCL (n= 212) and patients with unclassified DLBCL (n= 67) were obtained from the publicly available microarray
datasets GSE10846 and GSE56315. Mean expression±SD is shown in red. **p < 0.01 and ***p < 0.001. c, d Cdc20 and Cdh1 mRNA expression in
indolent and aggressive MCL. Cdc20 (c) and Cdh1 (d) gene expression levels of patients with indolent (n= 7) and aggressive MCL (n= 15)
were obtained from the GSE16455 dataset. Mean expression ± SD is shown in red. *p < 0.05. e, f Prognostic value of Cdc20 and Cdh1 mRNA
levels in terms of overall survival in DLBCL. The prognostic value of Cdc20 (e) and Cdh1 (f) was determined in DLBCL patients receiving R-
CHOP treatment from the Lenz cohort (n= 233) using Maxstat analysis (cut-off value used for Cdc20 is 11.679 and for Cdh1 8.319). Data were
analysed through genomicscape (http://genomicscape.com). g–j Immunohistochemical analysis of Cdc20 expression in primary DLBCL
patient samples. Immunohistochemical analysis of Cdc20 expression in a DLBCL patient. A ×4 and ×40 magnification is shown (g). Percentage
of Cdc20-positive lymphoma cells was counted in 34 DLBCL patients and plotted against the estimated prognosis according to the R-IPI score
of the patients (h). Percentage of Cdc20-positive cells was also plotted against the molecular subtype (i) and double-expresser status (j) in 27
DLBCL patients
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samples and a lower Cdh1 mRNA expression (Supplemental Fig. 1a).
These findings were also confirmed both at mRNA and protein levels
in a selected panel of DLBCL and MCL cell lines (Supplemental Fig. 1b,
c). Next, the effect of the specific APC/C inhibitor proTAME was
evaluated on the viability of the selected MCL and DLBCL cell lines. As
shown in Fig. 2a, a dose-dependent decrease in viability was observed
in all cell lines after 24 h of treatment. Among the MCL cell lines, the
Rec-1 cells were found the least sensitive to proTAME (IC-50 of 19.2
µM), while the Jeko-1 cells were the most sensitive with an IC-50 of
~5.2 µM. Most of the DLBCL cell lines have an IC-50 value around 6
µM, except for the SU-DHL-6 cells which were the most sensitive with
an IC-50 of 2.5 µM (Fig. 2b). This decreased viability was also
confirmed by performing cell counting (Supplemental Fig. 1d). The
effect of APC/C inhibition was also determined on apoptosis by using
an Annexin V/7′-AAD staining. A significant increase in apoptotic cells
was observed in all cell lines (Fig. 2c). Moreover, this induced
apoptosis seems to be caspase-3 mediated, as evidenced by a
significant increase in the percentage of active caspase-3-positive cells
after APC/C inhibition (Fig. 2d). Similar effects on viability and
apoptosis were observed after 48 h of treatment (Supplemental
Fig. 1e–h). Finally, the effect of pharmacological inhibition of the APC/
C was tested on primary patient cells obtained from four MCL and
three DLBCL patients. As shown in Fig. 2e, f, a dose-dependent
reduction in viability was observed in all patient samples after 72 h of
proTAME treatment. Patient characteristics can be found in Supple-
mental Table 1.
APC/C inhibition results in a metaphase arrest
To determine the underlying mechanisms of action, the effect of
proTAME on the activity of the co-activators was assessed by
determining the protein levels of the APC/C–Cdc20 substrate cyclin
B1 and APC/C–Cdh1 substrate Skp2. Cells were synchronised using a
double thymidine block and released into proTAME treatment.
Western blot analysis demonstrated that cyclin B1 protein levels
increased during mitotic arrest in all MCL and DLBCL human cell lines
used, as indicated by phosphorylation of the APC/C subunit APC3
(also known as Cdc27).34 Skp2 protein levels remained mostly
unchanged, except in the ABC–DLBCL cell line (Fig. 3a). In contrast, in
untreated synchronised cells, neither significant accumulation of
cyclin B1 or Skp2 levels was observed, nor was there an increase in
phosphorylation of APC3 (Supplemental Fig. 2). Together, these data
indicate that the induced mitotic arrest is proTAME-dependent, as
well as the effects seen on cyclin B1 and Skp2 protein levels. As the
APC/C is an important protein complex involved in the
metaphase–anaphase transition during mitosis, the effect on cell
cycle progression was investigated. The mitotic arrest was confirmed
by cell cycle analysis using a propidium iodide flow-cytometry
staining (Fig. 3b). To further validate these findings, a May–Grünwald
Giemsa staining was performed and cells in the metaphase were
quantified (Supplemental Fig. 3). A significant increase in the
percentage of cells in the metaphase after APC/C inhibition was
observed (Fig. 3c). These findings on synchronised cells demonstrate
that proTAME treatment induced metaphase arrest in DLBCL and
MCL cells.
Induced apoptosis is mediated by phosphorylation of Bcl-2 and
Bcl-xL
A prolonged metaphase is known to delay the activation of Cdk1,
which can then phosphorylate/inactivate several anti-apoptotic
proteins from the Bcl-2 family, thus resulting in the activation of
the intrinsic apoptotic pathway.35 The effect of proTAME
treatment on the expression and phosphorylation of Mcl-1, Bcl-2
and Bcl-xL was evaluated during mitotic arrest by western blot. No
clear difference in the total Bcl-2, Bcl-xL and Mcl-1 protein was
observed. Nevertheless, consistent with the prolonged activation
of Cdk1, an increase in phosphorylation of Bcl-2 and Bcl-xL was
observed during the mitotic arrest (Fig. 4a). In contrast, neither a
difference was observed in the cleaved Mcl-1 protein levels during
a mitotic arrest nor in the Cdc4 (also known as FBW7) protein
levels. Again, no changes in phosphorylation of Bcl-2 or Bcl-xL
were observed in the untreated synchronised cells (Supplemental
Fig. 2). Together, these data suggest that APC/C targeting induces
caspase-mediated apoptosis by inactivating the anti-apoptotic
protein Bcl-2 and Bcl-xL. Based on this, we next hypothesised that
proTAME might sensitise the DLBCL and MCL cell lines to a BH3
mimetic. To investigate this hypothesis, DLBCL and MCL cell lines
were treated with proTAME and the selective Bcl-2 inhibitor ABT-
199. In all three lymphoma subtypes, an increased percentage of
apoptotic cells was observed in the cells treated with proTAME
and ABT-199 compared with both single agents (Fig. 4b).
ProTAME enhances the anti-lymphoma activity of the Cdc20/Cdh1
inhibitor apcin and the standard-of-care agent doxorubicin
A previous study showed that simultaneous disruption of different
protein interactions of the APC/C might be a more effective tool for
inactivating this complex.36 Therefore, proTAME was combined with a
Cdc20/Cdh1 inhibitor, namely apcin, which prevents the co-
activator–substrate interaction. Different concentrations (IC-10, IC-30
and IC-50) of both agents were used to test the combinatory effect
(Supplemental Table 2). The combination of proTAME and apcin
significantly increased the effect of both single agents in all human
cell lines (Fig. 5a), with the MCL cell line being the most sensitive.
Moreover, this combinatory effect was found to be synergistic in all
cell lines, with combination indexes well below 1 for the relevant
concentrations. Next, to investigate the effect of APC/C inhibition on
the activity of clinically relevant drugs, we performed combination
studies with the standard-of-care agents doxorubicin and rituximab.
ProTAME treatment was found to significantly and synergistically
sensitise lymphoma cells of all the B cell NHL subtypes tested to
doxorubicin-mediated cell death, especially at higher concentrations
(Fig. 5b). Of interest, the MCL cell line Jeko-1 again seemed more
sensitive to the combination than the DLBCL cell lines SU-DHL-6 and
U2932. In contrast, rituximab showed only very minor cytotoxicity
in vitro, and this was not further enhanced when combining
rituximab with proTAME (Fig. 5c).
DISCUSSION
Even with recent improvements in the treatment of lymphoma
patients, no difference is detected in the overall survival of MCL
patients37 and there is still a poor outcome for 30–40% of the
Table 1. COX univariate and multivariate analysis of overall survival in
R-CHOP-treated DLBCL (n= 233) including Cdc20 gene expression
A. Univariate analysis Overall survival (n= 233)
Prognostic variable HR p-value
Cdc20 2.43 0.008
Age (>60 years) 2.2 <0.0001
GCB–ABC molecular subgroups 2.75 <0.0001
IPI 1.79 <0.0001
B. Multivariate analysis Overall survival (n= 233)
Prognostic variable HR p-value
Cdc20 2.91 0.01
Age (>60 years) 0.79 ns
GCB–ABC molecular subgroups 4.15 <0.0001
IPI 1.64 0.001
The prognostic factors were tested as a single variable (A) or multi variables
(B) using the COX-model. p-values and hazard ratios (HR) are shown. ns: not
significant at a 5% threshold
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DLBCL patients.3 The high proliferation rate of these lymphoma
cells provides the rationale to use selective antimitotic drugs as a
treatment option.37,38 In this study, the mitotic exit regulator APC/
C is identified as a novel, promising target in ABC–DLBCL,
GCB–DLBCL and MCL. From literature, it is known that the activity
of the APC/C depends on the interaction with the APC/C co-
activators. Changes in the expression/activation of one or both of
these co-activators subsequently result in alterations in the APC/C
activity.39 Thus, to investigate the involvement of the APC/C in
DLBCL and MCL disease, we investigated the expression of APC/C
co-activators Cdc20 and Cdh1 using publicly available gene
expression profiling data from DLBCL and MCL patients. We
demonstrated that the APC/C co-activator Cdc20 is significantly
overexpressed in DLBCL patients and in aggressive MCL patients
compared with indolent MCL. Moreover, high Cdc20 gene
expression was correlated with a poor survival outcome in the
DLBCL patients. Consistent with our results, high Cdc20 gene
expression was repeatedly shown to be associated with poor
prognosis in various other cancer types, including breast cancer,
multiple myeloma, non-small-cell lung cancer, etc.15–21 In contrast,
there is still some controversy about the role of Cdh1 in
tumorigenesis. Cdh1 is generally considered to be a tumour
suppressor.11 However, two studies showed that loss of Cdh1
function induces cell death and might be essential for tumour
development. Moreover, a recent study observed increased Cdh1
expression in primary MM cells.27,40,41 In our study, neither a
significant difference in Cdh1 mRNA expression was detected in









































































































































































Fig. 2 APC/C inhibition reduces DLBCL and MCL viability and induces caspase-3-mediated apoptosis. a, b Effect of proTAME treatment on cell
viability. MCL and DLBCL cell lines were treated for 24 h with proTAME (3, 6 and 12 µM) and the effect on viability was determined using a
CellTiter-Glo assay (a). The results are shown as % viability relative to control. The IC-50 values for each cell line were calculated using Prism (b).
c, d Effect of proTAME treatment on apoptosis. The effect of proTAME treatment on apoptosis (c) and percentage of active caspase-3- positive
cells (d) was determined after 24 h, using an Annexin V/7′-AAD staining, followed by flow-cytometric analysis, and active caspase-3 staining
followed by flow-cytometric analysis. The percentage of apoptotic cells are the sum of the percentage of Annexin V and Annexin V/7′-AAD
positive cells. The results shown in graphs a, c and d are the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 and ***p <
0.001. e, f The effect of proTAME treatment on primary patient samples. The viability of the proTAME-treated MCL (e) and DLBCL (f) patient
samples was determined after 24 h. The results are shown as % viability relative to control
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correlation between expression levels and survival. Importantly,
aggressive B-cell malignancies are a diverse group of lymphomas,
including many variants of DLBCL and MCL. There are enormous
differences in clinical behaviour and molecular mechanisms, as
well as response to treatment. Consequently, identification of new
prognostic markers is of utmost importance to achieve tailored
therapy.42 The Cox analysis in our study revealed that Cdc20 is an
independent prognostic factor in DLBCL and Cdc20 protein
expression seems to be linked to a poor prognosis in DLBCL
patients. Importantly, the prognostic value in DLBCL seems to be
irrespective of the molecular subtype and double expressers.
Based on these findings, Cdc20 could be a potential new, relevant
marker for poor prognosis in DLBCL patients. However, further
validation on protein level in a prospective study in larger patient
cohorts remains warranted. Together, our data indicate that Cdc20
is involved in DLBCL and MCL pathogenesis, thus supporting the
preclinical testing of APC/C targeting in these aggressive B-
cell NHLs.
The therapeutic potential of targeting the APC/C, either by
blocking the activation of the complex or the co-activators, has
Jeko-1 SU-DHL-6 U2932
APC3
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Fig. 3 Pharmacological inhibition of the APC/C with proTAME results in a metaphase arrest. a Effect of proTAME treatment on the substrates
of the APC/C co-activators Cdc20 and Cdh1. Expression of cyclin B1 and Skp2 was determined at different timepoints in the MCL and DLBCL
cell lines after synchronisation and release into proTAME treatment (3 µM in SU-DHL-6 and 6 µM in Jeko-1 and U2932). APC3 and β-actin were
used as indicators of mitotic arrest and loading control. Arrows show the phosphorylated APC3. One experiment representative of three is
shown (the results shown are from the same experiment as those shown in Fig. 4). Normalisation was performed with Image J and
quantification relative to the M condition is shown. Bars represent the mean± SD of three independent experiments. b, c Effect of proTAME
treatment on cell cycle progression. The effect on cell cycle progression was determined using PI staining on cell lines treated with 3 µM (SU-
DHL-6) or 6 µM (Jeko-1 and U2932) proTAME for the indicated timepoints after synchronisation (b). To further examine the effect on mitosis,
cytospins of these treated cells were stained with May–Grünwald Giemsa. For each sample, 3 × 100 cells were counted per cytospin.
Quantification of the percentage of cells in the metaphase is shown (c). The results shown in each graph are the mean ± SD of three
independent experiments. *p < 0.05 and **p < 0.01. M=mitosis, −4= 4 h before mitosis, −2= 2 h before mitosis, +3= 3 h after mitosis and
+6= 6 h after mitosis
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been examined in cancer using proTAME,15,26,27 withaferin A,43
NAHA (a hydroxamic acid derivative)44 and apcin.45 The small
molecule proTAME is the only true/selective APC/C inhibitor
known so far.26 ProTAME has already been described to cause a
prolonged metaphase in cancer cells.15,26 Consistent with these
observations, synchronised DLBCL and MCL cells released into
proTAME treatment were found to accumulate in the G2/M phase.
Western blot analysis of these cells demonstrated an increase in
cyclin B1 protein levels during this mitotic arrest, while Skp2 levels
are not or only slightly affected. The induced G2/M-phase arrest
was further investigated, and a significant increase in the
percentage of cells in the metaphase was observed. It is known
that cells in a prolonged metaphase can either undergo cell death
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Fig. 4 proTAME inactivates the anti-apoptotic proteins Bcl-2 and Bcl-xL and sensitises MCL and DLBCL cells to venetoclax. a Effect of proTAME
treatment on the expression and phosphorylation of Bcl-2, Bcl-xL and Mcl-1. The expression of Mcl-1, Cdc4, Bcl-2 and Bcl-xL protein and
phosphorylation of Bcl-2 and Bcl-xL was determined at different timepoints in the synchronised MCL and DLBCL cell lines after proTAME
treatment (3 µM in SU-DHL-6 and 6 µM in Jeko-1 and U2932) using western blot. APC3 and β-actin were used as indicators of mitotic arrest
and loading control. Arrows show the phosphorylated APC3. One experiment representative of three is shown (the results shown are from the
same experiment as those shown in Fig. 3). Normalisation was performed with Image J and quantification relative to the M condition is shown.
Bars represent the mean± SD of three independent experiments. M=mitosis, −4= 4 h before mitosis, −2= 2 h before mitosis, +3= 3 h after
mitosis and +6= 6 h after mitosis, ND= not detected. b The anti-lymphoma effect of APC/C targeting in combination with the BH3 mimetic
ABT-199. Apoptosis of proTAME (pT) and ABT-199-treated Jeko-1, SU-DHL-6 and U2932 cells was determined after 48 h using Annexin V/7′-
AAD staining followed by flow-cytometric analysis. The sum of the percentage of Annexin V and Annexin V/7′-AAD-positive cells are shown.
The results shown in each graph are the mean ± SD of four independent experiments. Each combination was compared with both single
agents. **p < 0.01 and ***p < 0.001
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critical factor in this decision-making. When Cdc20 levels increase
during the metaphase, cyclin B1 will be degraded, resulting in
Cdk1 inactivation and mitotic exit.46 On the other hand, a
prolonged activation of the cyclin B1–Cdk1 complex occurs when
cells are arrested in the metaphase, resulting in the phosphoryla-
tion and inactivation of Bcl-2 and Bcl-xL, and subsequent
activation of the intrinsic apoptotic pathway.35,47,48 Consistent
with the above, the proTAME-induced prolonged metaphase in
DLBCL and MCL cells is accompanied by a dose-dependent
decrease in viability and increase in caspase-mediated apoptosis.
Western blot analysis confirmed the phosphorylation of both Bcl-2
and Bcl-xL. In contrast, Mcl-1 and Cdc4 levels remained mostly
unchanged during the mitotic arrest, indicating that the
Cdc4–Mcl-1 axis is most likely not involved in proTAME-induced
cell death. These findings provide evidence that APC/C targeting
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Fig. 5 APC/C inhibition enhances the anti-lymphoma activity of the Cdc20/Cdh1 inhibitor apcin and the clinically relevant agent doxorubicin.
a–c The anti-lymphoma effect of APC/C targeting in combination with apcin, doxorubicin or rituximab. Apoptosis of proTAME (pT) and/or
apcin (a), doxorubicin (b) or rituximab (c) treated with Jeko-1, SU-DHL-6 and U2932 cells was determined after 48 h using Annexin V/7′-AAD
staining followed by flow-cytometric analysis. The sum of the percentage of Annexin V and Annexin V/7′-AAD-positive cells are shown. The
results shown in each graph are the mean ± SD of four independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 when compared with
both single agents. Combination index (CI) values were calculated for the different drug concentrations by the Chou and Thalalay method
using CompuSyn 1.0 software (nd: not determined, CI ≤ 1: synergistic)
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cells, resulting in the accumulation of cyclin B1 and a prolonged
activation of Cdk1, followed by phosphorylation of Bcl-2 and Bcl-
xL and eventually cell death.
To further ensure that cells will not re-enter the cell cycle after
the metaphase arrest induced by proTAME, combination studies
were performed. Previously, we and others demonstrated that
inactivation of the APC/C is more effective when multiple protein
interactions are simultaneously disrupted using proTAME and
apcin.15,36 ProTAME blocks the interaction between the APC/C and
its co-activators, while apcin inhibits the interaction between the
co-activators and their substrates.36 This combination resulted in a
synergistic anti-lymphoma effect in all cell lines. Other studies in
myeloma also showed a combinatory effect with the anti-
myeloma agents melphalan, vincristine, etoposide and the
topoisomerase II inhibitor doxorubicin.15,27 Topoisomerase IIα is
identified as a Cdh1 substrate and both proTAME and knockdown
of Cdh1 significantly enhance the sensitivity of cancers cells to
topoisomerase II inhibitors.49 Consistent with these findings,
proTAME was also found to sensitise all lymphoma cell lines
tested to doxorubicin. Combining proTAME with rituximab did not
demonstrate any additional effect. This could be explained by the
minor effects that rituximab alone had on the different cell lines
in vitro. Consistently with our data, others also observed no or
only minor effects when using rituximab as monotherapy in
DLBCL cell lines.50 The anti-lymphoma effect of proTAME
combined with a novel agent in clinical development in DLBCL
and MCL, namely the selective Bcl-2 inhibitor venetoclax, was also
tested. ProTAME strongly and significantly potentiated the anti-
lymphoma activity of venetoclax in all cell lines tested, even in the
highly sensitive ABC–DLBCL cell line U2932.
To further validate the therapeutic potential of targeting of APC/C
in DLBCL and MCL, we acknowledge that in vivo studies are required.
Unfortunately, when it comes to the in vivo use of proTAME, there are
some concerns. ProTAME has not yet been optimised for in vivo
studies, since this prodrug is activated intracellularly by esterases and
the active form (TAME) is not cell permeable.26 These enzymes can be
present in the bloodstream, thus limiting the in vivo use of proTAME.
A possible solution could be to pack (pro)TAME in a liposomal vesicle,
such as the vesicle used for liposomal doxorubicin in the treatment of
aggressive B-cell lymphoma.51 Another general concern is that
inhibition of the APC/C will most likely affect all dividing cell types.
To avoid these off-target effects, liposomal (pro)TAME could be
altered, so that it can only be recognised by CD20+B cells. This would
give the advantage of specifically targeting the lymphoma cells like
rituximab.
In conclusion, this study demonstrates that high Cdc20 expression
correlates with a poor prognosis in the aggressive B-cell malignancy
DLBCL. We also provide evidence that APC/C targeting in DLBCL and
MCL cells results in a prolonged metaphase followed by apoptosis
and sensitises the lymphoma cells to the clinically relevant agents
doxorubicin and venetoclax. Together, this study suggests that the
APC/C is a potential new target in these cancer types, making it a
promising target for further preclinical research.
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